

Technology Advisory Committee A Interests Register

Talazoparib for treating HER2-negative locally advanced or metastatic breast cancer with germline BRCA1/2 mutations [ID1342]

Publication Date: 21 February 2024

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Interest ceased	Comments
Professor Andrew Tutt	Clinical expert	Direct – financial	<p><u>AZ</u></p> <p>Professor Andrew Tutt receives from the ICR a share of royalties/payments made to ICR by AZ from sales of olaparib and other PARP inhibitors.</p> <p><u>Pfizer</u></p> <p>-Personal fees /Advisory Board related to targeted therapies in DNA repair deficient.</p> <p><u>Vertex</u></p> <p>- Personal fees from /Advisory Board related to targeted therapies in DNA repair deficient.</p>	29/12/2022	N/A	It was agreed that Andrew's declaration would not prevent him from providing expert advice to the committee.

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Interest ceased	Comments
			<p><u>Artios</u> - Personal fees / Advisory Board related to targeted therapies in DNA repair deficient.</p> <p><u>Prime Oncology</u> - Personal fees / Advisory Board related to targeted therapies in DNA repair deficient.</p> <p><u>Inbiomotion</u> - Personal fees / Scientific Ad Board function and stock options</p> <p><u>MD Anderson</u> - personal fees / Moon shot Breast Cancer scientific advisory board honoraria.</p> <p><u>Medscape Education honorarium from Merck educational grant</u> - personal fees / speaker for a video series tentatively titled "Understanding the</p>			

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Interest ceased	Comments
			<p>Rationale for PARP Inhibitors and their Combination with Immunotherapy in the Treatment of Various Solid Tumours</p> <p><u>SABCS Mini Symposium</u>-speaker honorarium</p> <p><u>EMPartners</u>-</p> <p>Personal fees / Advisory Board</p> <p><u>Gilead</u>:</p> <p>-Personal fees for Ad Board & payments to my institution</p> <p><u>GBCC 2022</u></p> <p>-Speaking role personal honorarium</p> <p><u>Cancer Panel</u></p> <p>-Speaker personal honorarium</p>			

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Interest ceased	Comments
			<p><u>Research to Practice</u></p> <p>-Personal honorarium for research survey</p> <p><u>AACR Team prize</u></p> <p>-Personal honorarium for Team prize</p> <p><u>Private practise @ HCA – LOC-</u></p> <p>-Private oncology hospital clinics in London treating patients with germline BRCA1/2 mutations in breast cancer involving all forms of systemic therapy, including PARP inhibitors licensed in breast cancer indications.</p> <p><u>Director, Breast Cancer Now Research Unit, King's College London &</u></p> <p><u>Director, Breast Cancer Now Research Centre, The</u></p>			

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Interest ceased	Comments
			<p><u>Institute of Cancer Research, London</u></p> <p>-Full time dual role as Director across two Institutes. Salary paid.</p> <p><u>Honorary Consultant Clinical Oncologist @ Guys' & St Thomas Hospital NHS Foundation Trust-</u></p> <p>-Treating patients in NHS capacity.</p>			
Professor Andrew Tutt	Clinical expert	Direct – Nonfinancial	<p>ESMO Guidelines - Committee Member</p> <p>ESMO Breast 2022 - Scientific Committee</p> <p>ESMO 2023 Planning – Scientific Committee Member</p> <p>NCRI Strategy Committee – Member</p>	29/12/2022	N/A	It was agreed that Andrew's declaration would not prevent him from providing expert advice to the committee.

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Interest ceased	Comments
			<p>Early Breast Cancer Trialists' Collaborative Group- Member</p> <p>Global Study Chair OlympiA Trial Steering Committee</p> <p>CRUK- Expert panel member / chair for Clinical Research Expert Review Panel</p> <p>Director, Breast Cancer Now Research Unit, King's College London</p> <p>Director, Breast Cancer Now Research Centre, The Institute of Cancer Research, London</p> <p>Honorary Consultant Clinical Oncologist @ Guys' & St Thomas Hospital NHS Foundation Trust,</p> <p>Honorary Consultant Clinical Oncologist @ The Royal Marsden Hospital NHS Foundation Trust</p>			

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Interest ceased	Comments
Professor Andrew Tutt	Clinical expert	Indirect	<p><u>AstraZeneca</u> -Financial support to my academic & hospital institutions for costs associated with global academic study chair and local site costs for OlympiA trial / Travel expenses related to any trial related travel / Payments to Institution through Breast International Group for trial conduct in OlympiA trial and through CRO's for commercial parp inhibitor trials / AstraZeneca-royalties paid to Institute of Cancer Research for the use of parp inhibitors in DNA deficient cancers, and personally to me through ICR rewards to Inventor's scheme.</p> <p><u>Merck KGAA</u> -Local site trial support costs associated with clinical trial DNA</p>	29/12/2022	N/A	It was agreed that Andrew's declaration would not prevent him from providing expert advice to the committee.

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Interest ceased	Comments
			<p><u>Medivation</u> - Financial support for research at ICR</p> <p><u>Myriad Genetics</u> - Financial support for research at ICR</p> <p><u>AZ ESMO Symposium</u> Paid to ICR for speaker role</p> <p><u>VJ oncology</u> Roundtable- payment to institution</p> <p><u>GE Healthcare</u> Meeting – payment to institution</p> <p><u>Gilead:</u> -Personal fees for Ad Board & payments to my institution</p>			

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Interest ceased	Comments
			<p><u>Innovation in Breast Cancer Symposium:</u></p> <p>-Fees to my King's Institution for speaking role at conference</p> <p><u>SABCS 2021 conference:</u></p> <p>-Fees to Institute of Cancer Research for speaking role at conference.</p> <p><u>Breast Cancer Now Charity</u></p> <p>- Grant funded to study homologous recombination deficient breast and other cancers, BCN receive payments through AstraZeneca related to PARP inhibitor patents.</p> <p><u>CRUK</u></p> <p>- Grant funded to study homologous recombination deficient breast and other cancers, CRUK receive payments through</p>			

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Interest ceased	Comments
			AstraZeneca related to PARP inhibitor patents / personal fees / Honoraria associated with function as Deputy Chair and reviewer for CRUK clinical research.			
Dr Jennifer Glendenning	Clinical Expert	Indirect	Advisory board payments Exact Sciences and Roche.	22/11/2022	N/A	It was agreed that Jennifer's declaration would not prevent her from providing expert advice to the committee.